# Ranolazine Mediated PVC Reduction in Ischemic Heart Disease

> **NCT02360397** · PHASE2 · COMPLETED · sponsor: **Kent Hospital, Rhode Island** · enrollment: 6 (actual)

## Conditions studied

- Ventricular Premature Complexes
- Myocardial Ischemia

## Interventions

- **DRUG:** ranolazine

## Key facts

- **NCT ID:** NCT02360397
- **Lead sponsor:** Kent Hospital, Rhode Island
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-12
- **Primary completion:** 2017-12-31
- **Final completion:** 2018-02-23
- **Target enrollment:** 6 (ACTUAL)
- **Last updated:** 2020-01-29

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02360397

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02360397, "Ranolazine Mediated PVC Reduction in Ischemic Heart Disease". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT02360397. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*